CLDN18 and gastric cancer: Results from the Phase III GLOW and SPOTLIGHT studies both demonstrated that the chemotherapy regimen including zolbeximab conferred clinically meaningful PFS and OS benefits in Chinese patients with advanced gastric cancer (GC) or gastroesophageal junction cancer (GEJC) who were CLDN18.2-positive and HER2-negative, with a favorable safety profile.